Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.


Listen to the latest hemonc news from international experts

SOHO 2021: amyloidosis treatment updates

Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of chemotherapeutic agents, and improved patient selection for autologous stem cell transplantation (ASCT); however, for patients who are diagnosed at later stages or who are ineligible for ASCT the prognosis is poorer. Recently, the introduction of daratumumab has shown promising results for patients with both newly diagnosed and relapsed/refractory amyloidosis and there have been a number of Phase II/III trials aiming to help guide treatment decision-making and improve patient outcomes.

In today’s podcast, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, gives an overview of key updates in the treatment landscape of amyloidosis, as presented at the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

Date: 30th September 2021

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter